Praziquantel and the benzodiazepine Ro 11-3128 do not compete for the same binding sites in schistosomes

Parasitology

Volumn 135, Issue 1, 2008, Pages 47-54

  Pica Mattoccia, L ^a   Ruppel, A ^b   Xia, C M ^a   Cioli, D ^a,c  

^a Institute of Cell Biology   (Italy)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CNR   (Italy)

Author keywords

Benzodiazepine; Calcium channel blockers; Cytochalasin D; Drug competition; Drug inhibition; Praziquantel; Ro 11 3128; Schistosoma japonicum; Schistosoma mansoni

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHALASIN D; MECLONAZEPAM; PRAZIQUANTEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHISTOSOMA; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS;

ANIMALS; ANTHELMINTICS; BENZODIAZEPINONES; BINDING SITES; CALCIUM CHANNEL BLOCKERS; CYTOCHALASIN D; DRUG INTERACTIONS; FEMALE; MALE; MICE; MOVEMENT; NUCLEIC ACID SYNTHESIS INHIBITORS; PRAZIQUANTEL; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SURVIVAL ANALYSIS;

SCHISTOSOMA; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI;

EID: 37249093155     PISSN: 00311820     EISSN: 14698161     Source Type: Journal    
DOI: 10.1017/S0031182007003514     Document Type: Article

References (20)

1. Baard, A. P., Sommers, D. K., Honiball, P. J., Fourie, E. D. and du Toit, L. E. (1979). Preliminary results in human schistosomiasis with Ro 11-3128. South African Medical Journal 55, 617-618.
2. Bennett, J. L. (1980). Characteristics of antischistosomal benzodiazepine binding sites in Schistosoma mansoni. Journal of Parasitology 66, 742-747.
3. Bricker, C. S., Depenbusch, J. W., Bennett, J. L. and Thompson, D. P. (1983). The relationship between tegumental disruption and muscle contraction in Schistosoma mansoni exposed to various compounds. Zeitschrift für Parasitenkunde 69, 61-71.
4. Cioli, D. (2000). Praziquantel: is there real resistance and are there alternatives ? Current Opinion in Infectious Diseases 13, 659-663.
5. Darragh, A., Lambe, R., Brick, I. and Downie, W. W. (1981). Reversal of benzodiazepine-induced sedation by intravenous Ro 15-1788. Lancet 2, 1042.
6. Doenhoff, M. J. and Pica-Mattoccia, L. (2006). Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Review of Anti-Infective Therapy 4, 199-210.
7. Fenwick, A., Rollinson, D. and Southgate, V. (2006). Implementation of human schistosomiasis control: challenges and prospects. Advances in Parasitology 61, 567-622.
8. Gönnert, R. and Andrews, P. (1977). Praziquantel, a new board-spectrum antischistosomal agent. Zeitschrift für Parasitenkunde 52, 129-150.
9. Greenberg, R. M. (2005). Are Ca2+ channels targets of praziquantel action? International Journal for Parasitology 35, 1-9.
10. Gryseels, B., Mbaye, A., De Vlas, S. J., Stelma, F. F., Guissé, F., Van Lieshout, L., Faye, D., Diop, M., Ly, A., Tchuem-Tchuenté, L. A., Engels, D. and Polman, K. (2001). Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance ? An overview of the evidence. Tropical Medicine and International Health 6, 864-873.
11. Hunkeler, W., Mohler, H., Pieri, L., Polc, P., Bonetti, E. P., Cumin, R., Schaffner, R. and Haefely, W. (1981). Selective antagonists of benzodiazepines. Nature, London 290, 514-516.
12. Kohn, A. B., Anderson, P. A. V., Roberts-Misterly, J. M. and Greenberg, R. M. (2001). Schistosome calcium channel β subunits: unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. Journal of Biological Chemistry 276, 36873-36876.
13. Noel, F., Mendonca-Silva, D. L., Thibaut, J. P. and Lopes, D. V. (2007). Characterization of two classes of benzodiazepine binding sites in Schistosoma mansoni. Parasitology 134, 1003-1012.
14. O'Boyle, C., Lambe, R. and Darragh, A. (1985). Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam. European Journal of Clinical Pharmacology 29, 105-108.
15. Pax, R., Bennett, J. L. and Fetterer, R. (1978). A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schmiedebergs Archives of Pharmacology 304, 309-315.
16. Pica-Mattoccia, L. and Cioli, D. (2004). Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. International Journal for Parasitology 34, 527-533.
17. Pica-Mattoccia, L., Valle, C., Basso, A., Troiani, A. R., Vigorosi, F., Liberti, P., Festucci, A. and Cioli, D. (2007). Cytochalasin D abolishes the schistosomicidal activity of praziquantel. Experimental Parasitology 115, 344-351.
18. Sabah, A. A., Fletcher, C., Webbe, G. and Doenhoff, M. J. (1986). Schistosoma mansoni: chemotherapy of infections of different ages. Experimental Parasitology 61, 294-303.
19. Stelma, F. F., Talla, I., Sow, S., Kongs, A., Niang, M., Polman, K., Deelder, A. M. and Gryseels, B. (1995). Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. American Journal of Tropical Medicine and Hygiene 53, 167-170.
20. Stohler, H. R. (1978). Ro 11-3128, a novel schistosomicidal compound. In Current Chemotherapy, Proceedings of the 10th Congress of Chemotherapy, Vol. 1 (ed. Siegenthaler, W. and Lüthy, R.), pp. 147-148. American Society for Microbiology, Washington.